Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012

Date: February 29, 2012
Pages: 70
Price:
US$ 1,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P23EB02847DEN
Leaflet:

Download PDF Leaflet

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2012. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope
  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the last six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 PHARMACEUTICALS & HEALTHCARE, GLOBAL, DEAL SUMMARY,

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2012
2.2 Pharmaceuticals & Healthcare, Global, Top Deals, January 2012
  2.2.1 Bristol-Myers Squibb Completes Acquisition Of Inhibitex For $2.5 Billion
  2.2.2 Fresenius Medical Completes Private Placement Of Senior Unsecured Notes For $1.8 Billion
  2.2.3 Amgen To Acquire Biotechnology Company, Micromet For $1.16 Billion
  2.2.4 Celgene To Acquire Avila Therapeutics, Biotechnology Company
  2.2.5 FORMA Therapeutics Enters Into R&D Agreement With Boehringer Ingelheim
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, January 2012

3 PHARMACEUTICALS AND HEALTHCARE, GLOBAL, DEALS, SUMMARY, BY TYPE

3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2012
  3.1.1 Top M&A Deals in January 2012
  3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2011-January 2012
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2012
  3.2.1 Top Equity Offering Deals in January 2012
  3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2011 - January 2012
3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, January 2012
  3.3.1 Top Debt Offering Deals in January 2012
  3.3.2 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, August 2011 - January 2012
3.4 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2012
  3.4.1 Top PE/VC Deals in January 2012
  3.4.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2012
  3.4.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2012
  3.4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2011 - January 2012
  3.4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2011 - January 2012

4 PHARMACEUTICALS & HEALTHCARE, GLOBAL, PARTNERSHIP DEALS, JANUARY 2012

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2012
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2011 - January 2012
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2012
  4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2012
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), August 2011 - January 2012
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2011 - January 2012

5 PHARMACEUTICALS & HEALTHCARE, GLOBAL, LICENSING AGREEMENTS, JANUARY 2012

5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2012
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2012
  5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2012
  5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2012
  5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2012
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2011 - January 2012
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2011 - January 2012
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2011 - January 2012
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2011 - January 2012

6 PHARMACEUTICALS & HEALTHCARE, GLOBAL, DEAL SUMMARY BY THERAPY AREA

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2012
  6.1.1 Oncology - Deals of the Month
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2012
  6.2.1 Central Nervous System - Deals of the Month
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2012
  6.3.1 Infectious Diseases - Deals of the Month
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2012
  6.4.1 Cardiovascular - Deals of the Month
6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2012
  6.5.1 Immunology - Deals of the Month
6.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, January 2012
  6.6.1 Metabolic Disorders - Deals of the Month
6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, January 2012
  6.7.1 Gastrointestinal - Deal of the Month

7 DEAL SUMMARY BY GEOGRAPHY

7.1 Pharmaceuticals & Healthcare, North America Deals, January 2012
  7.1.1 North America - Deals of the Month
7.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2012
  7.2.1 Europe - Deals of the Month
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2012
  7.3.1 Asia-Pacific - Deals of the Month
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2012
  7.4.1 Rest of the World - Deals of the Month

8 PHARMACEUTICALS & HEALTHCARE, GLOBAL, TOP FINANCIAL ADVISORS

8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2011 - January 2012
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2011 - January 2012

9 FURTHER INFORMATION

9.1 Methodology
9.2 About GlobalData
9.3 Contact Us
9.4 Disclosure information
9.5 Disclaimer

LIST OF TABLES

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 2: Pharmaceuticals & Healthcare, Global, Top Deals, January 2012
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2012
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2012
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2011 - January 2012
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2012
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 10: Pharmaceuticals & Healthcare, Global, Debt Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 11: Pharmaceuticals & Healthcare, Global, Top Debt Offering Deals, January 2012
Table 12: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal values (US$ m), August 2011 - January 2012
Table 13: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 14: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2012
Table 15: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2011 - January 2012
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2012
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2011 - January 2012
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 21: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2012
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
Table 24: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2011 - January 2012
Table 25: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2011 - January 2012
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
Table 28: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Deal Value, January 2012
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2012
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2012
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), August 2011 - January 2012
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2012
Table 33: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2011 - January 2012
Table 34: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2012
Table 35: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 37: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 38: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 39: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 42: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 43: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 44: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 45: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Table 47: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2011 - January 2012

LIST OF FIGURES

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%),January 2012
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 4: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2011 - January 2012
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 9: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 10: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2011 - January 2012
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), January 2012
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2011 - January 2012
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2011 - January 2012
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2012
Figure 25: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 26: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 27: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 28: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 29: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 30: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 31: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 32: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 33: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 34: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 35: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 36: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2011 - January 2012
Figure 37: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2011 - January 2012

Ask Your Question

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: